Selected Medicines in Development for Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States. COPD is a chronic lung disease characterized by progressive limitations of the airflow in and out of the lungs, and increased shortness of breath as the disease progresses.

Alzheimer’s Disease Clinical Trials

The 108 clinical trials listed here include 65 that have not yet started recruiting patients or are just now seeking volunteers to participate and another 43 that are active, but not recruiting new patients. This information is potentially valuable to patients still seeking possible treatments for Alzheimer’s disease. It provides a new therapeutic option to discuss with physicians.

Learn More About Medicines in Development for Women

America's pharmaceutical research and biotechnology companies are developing 851 medicines for diseases that disproportionately affect American women. The medicines in the pipeline for women (either in clinical trials or awaiting review by the Food and Drug Administration) include:

PhRMA Principles on Conduct of Clinical Trials

Developing new therapies to treat disease and to improve quality of life is a long and complex process. A critical part of that process is clinical research, the study of a pharmaceutical product in humans. Without clinical research studies, no new medicines could be made available to patients.

Conduct of Clinical Trials

Learn More About Medicines in Development for Rare Diseases

Learn More About Medicines in Development for Parkinson's Disease

America’s biopharmaceutical research companies are currently developing 37 medicines to help the estimated 1.5 million Americans living with Parkinson’s Disease, a motor system disorder resulting from the loss of dopamine-producing brain cells. All of the medicines are either in clinical trials or awaiting review by the U.S. Food and Drug Administration.

Learn More About Medicines in Development for Mental Illnesses

America’s biopharmaceutical research companies are developing 187 medicines to help the nearly 60 million American adults now suffering from some form of mental illness—from anxiety to depression and from schizophrenia to addictive disorders, such as dependence on alcohol or drugs. All of the medicines are either in clinical trials or awaiting review by the Food and Drug Administration.

Read More About Medicines in Development for Heart Disease & Stroke

Every 39 seconds an American dies from cardiovascular disease, and more than 83 million Americans have at least one type of the disease, the American Heart Association (AHA) reports. However, death rates from heart disease and stroke are falling, thanks in large part to new medicines. Advances in medicine have helped cut deaths from heart disease by one third between 2001 and 2011, according to the Centers for Disease Control and Prevention (CDC).

Read More About Medicines in Development for Diabetes

America’s biopharmaceutical research companies currently are developing 180 innovative new medicines to help the nearly 400 million people who have diabetes worldwide. These medicines in development – all either in clinical trials or under review by the Food and Drug Administration (FDA) – include 30 for type 1 diabetes, 100 for type 2 and 52 for diabetes-related conditions, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Pages

Subscribe to RSS - Innovation